The US Food and Drug Administration (FDA) has approved Dexcom’s next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for use in people aged two years and above with all types of diabetes.
The company has reduced the size of the wearable device by 60% compared to its previous generation, Dexcom G6.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
With fewer components, Dexcom G7 offers a 30-minute sensor warmup time along with a 12-hour grace period for replacing finished sensors, which provides smoother transitions between sessions.
It features a redesigned and simplified mobile app, which includes integration with Dexcom Clarity, as well as improved alert settings for enhanced discretion.
The advanced device also includes a new, redesigned optional receiver with a smaller, easy-to-read display.
Individuals above the age of two can wear the device on the back of the upper arm and individuals between two and 17 can also wear it on the upper buttocks.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFeatures of the Dexcom G6 that the Dexcom G7 also includes are no finger sticks, scanning or calibration. It can also be easily integrated with connected CGM ecosystems, such as Garmin, Apple Watch and other digital health apps.
It automatically sends real-time glucose readings to a compatible display device every five minutes.
Additionally, Dexcom G7 offers remote monitoring and allows users to share glucose data with up to ten followers.
Dexcom chairman, president and CEO Kevin Sayer said: “For more than a decade, we’ve pioneered generation after generation of sensing technology that consistently delivers improved accuracy, reliability and a simpler user experience, giving people greater control of their diabetes.
“When we set out to design G7, our goal was simple: to make the most powerful, easy-to-use CGM available for people with diabetes, whether they have Type 1 or Type 2. G7 delivers squarely on that promise.”
The company is currently working with its insulin pump partners to integrate G7 into existing and future automated insulin delivery systems.
It is planning to launch Dexcom G7 in the US early next year.
